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Abstract
Introduction: Modern studies demonstrate an epidemiological and pathogenetic role of systemic hormonal and met-
abolic disorders in men with prostate adenoma (PA), so it is obvious that a pharmacotherapeutic correction of these 
disorders can increase the efficacy of the traditional therapy of the disease.
Aim of study: To investigate the frequency, relationships among themselves and with PA local parameters of key sys-
temic hormonal and metabolic disorders (obesity, insulin resistance, testosterone deficiency, vitamin D deficiency) and 
to develop practical algorithms for optimizing diagnosis and management based on an integrative approach.
Material and Methods: The results of a comprehensive examination of 160 patients with PA (main group; average age 
62.3 ± 4.2 years) and 30 healthy men without PA of the same age (control group), including: collection of anamnesis 
and complaints; questionnaires; physical, hormonal and sonographic studies, – are presented. Pharmacotherapeutic 
correction methods were tested in some patients of the main group. The data was processed using descriptive and 
comparative statistics.
Results and Discussion: In the patients with PA, a significantly higher frequency of concomitant systemic hormonal 
and metabolic disorders formed at a younger age was established, compared to the men without PA, and significantly 
worse local characteristics of PA compared to the patients with PA without such (p < 0.05). Reliable connections of 
some studied systemic hormonal and metabolic disorders with one another and with local parameters of PA (p < 0.05) 
were revealed. A more severe vitamin D deficiency in the patients with PA compared to the control group was revealed, 
and the safety and a significant positive effect of its drug compensation on the parameters of hormonal and metabolic 
status and PA in D-deficient men with PA were shown (p < 0.05).
Conclusion: The results of the study confirm an important role of the studied systemic hormonal and metabolic disor-
ders in the pathogenesis of PA and the need for their diagnosis and pharmacotherapeutic correction in all patients with 
PA on the basis of an integrative approach, according to the proposed algorithms.
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Introduction
Prostate adenoma (PA) is one of the most common disea-
ses of aging men, negatively affecting their life quality 
(Lopatkin 2009; Alyaev 2016).
However, the revolutionary breakthrough of modern 
pharmacology gave clinicians effective drugs for drug 
correction of the symptoms of the disease, which led to a 
significant reduction in the need for its surgical treatment, 
and the basis of modern traditional pharmacotherapy of 
PA are drugs affecting directly and/or predominantly the 
vesico-urethro-prostatic segment of the urogenital tract 
(α-1-blockers, M-cholinolytics, inhibitors of 5-α-reduc-
tase, β-3-adrenomimetics, phytopreparations) (Lopatkin 
2009; Alyaev 2016).
Nevertheless, the current standard pharmacotherapy of 
PA is often not effective enough for a number of patients, 
especially those with systemic hormonal and metabolic 
disorders (obesity, insulin resistance, testosterone defici-
ency, vitamin D deficiency), which tends to increase in 
frequency in the male population and significantly reliably 
correlate with one another, as well as with the frequency 
and severity of PA (Park et al. 2008; Gorbachinsky et al. 
2010; Vignozzi et al. 2012; Espinosa 2013; Tyuzikov and 
Kalinichenko 2016; Udensi and Tchounwou 2016; Wang 
et al. 2016; Zou et al. 2016; Ngai et al. 2017).
In this regard, new concepts of PA etiopathogenesis are 
being formed today from the standpoint of an integrative 
approach, which implies the most important role of the 
above-mentioned systemic disorders in the pathogene-
sis of hormonal and metabolic imbalance in the prostate 
gland, leading to PA and its further independent progres-
sion (the theory of cholesterol imbalance, the theory of 
subclinical chronic inflammation, the theory of oxidative 
stress, etc.), which reflects the modern evolution of clas-
sical theories of PA etiopathogenesis, many of which are 
also hormonal by nature (the theory of androgen-estrogen 
imbalance, dihydrotestosterone theory, the theory of stro-
mal-epithelial relationships) (Ruan et al. 2011; Gacci et 
al. 2015; Russo et al. 2015; Tyuzikov et al. 2015; Fu et 
al. 2016; Zhao et al. 2016a, b). The available data from 
foreign literature allow us to conclude that integrative 
assessment of a hormonal and metabolic status and sub-
sequent pharmacotherapeutic correction of the identified 
systemic hormonal and metabolic disorders in patients 
with PA can be considered as a more effective therapeutic 
option than the current strategy of standard pharmacothe-
rapy; besides, it can have potential preventive effects in 
this disease. In the Russian scientific literature, there is 
a clear shortage of scientific publications on this topic, 
which makes the relevance of this study obvious.
Aim of study
To investigate the frequency, relationships among them-
selves and with local parameters of PA of the key sys-
temic hormonal and metabolic disorders (obesity, insulin 
resistance, testosterone deficiency, vitamin D deficiency) 
and to develop practical algorithms for optimizing diag-
nosis and management based on an integrative approach.
Material and methods
The work was organized and carried out in accordance 
with the legal acts and guidelines governing the conduct 
of clinical trials in the Russian Federation.
All the patients who participated in the study group un-
til the end of the study, as well as the men in the control 
group, had been pre-informed about the goals and objecti-
ves of the study, and each of them had signed an informed 
consent to participate in the study and to have his personal 
research results used for a further statistical analysis.
The work is based on the clinical observations, the 
results of a complex examination and medical treatment 
of the men with PA and systemic hormonal and metabo-
lic disorders, performed in the period 2016–2018 in the 
outpatient departments of the Clinic of Urology of Kursk 
State Medical University. The total number of the exa-
mined cohort was 190 men, of which 160 patients with PA 
made up the main group, and 30 healthy men without PA 
(control group). The study was on-going, prospective and 
full-design in nature. The results of a comprehensive sur-
vey of the men of the control group were taken as normal 
reference values of the studied indicators.
Criteria for inclusion in the study:
• The presence of PA in combination with the stud-
ied hormonal and metabolic disorders (obesity, 
insulin resistance, testosterone deficiency, vitamin 
D deficiency);
• The absence of diabetes mellitus resistant to the 
standard therapy;
• No history of surgical operations, neurological dis-
eases or injuries (and their consequences) of the pel-
vic area and perineum.
Criteria for exclusion from the study:
• The presence of the prostate middle lobe (intravesi-
cal growth of PA);
• Complicated course of PA, including the presence 
of acute urinary retention (AUR) in the history, 
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even though it happened once and/or was stopped 
by medication;
• The presence of absolute indications for surgical 
treatment of PA, according to the results of a com-
prehensive examination of the patient;
• Existing or suspected prostate cancer (total blood 
PSA > 4 ng/ml);
• Any pharmacotherapy for PA performed at least 6 
months before hands.
Statistical processing of the age index of the control 
group of men without PA (n = 30) rendered an average age 
of 58.3 ± 3.5 years (confidence interval being 0.95|4869), 
and for the patients with PA of the main group (n = 160), 
an average age was 62.3 ± 4.2 years (confidence interval 
being 0.95|45–75) (p < 0.05) (Table 1).
The distribution of patients with PA by the severity of 
LUTS/PA, quality of life index and assessment of noctu-
ria in them are presented in Tables 2–3.
Complaints and anamnestic data on generally accepted 
medical techniques were collected from all the patients 
before the examination and treatment.
To objectify and assess the severity of symptoms of 
the lower urinary tract associated with PA (LUTS/AP), as 
well as the quality of life due to them, a questionnaire was 
conducted according to the scale of the assessment of the 
symptoms of prostate diseases (IPSS-LQ). To assess the 
possible symptoms of age-related testosterone deficiency 
in men, the AMS (Aging Males Symptoms) questionnaire 
was used. All the men underwent a General physical cli-
nical examination according to the standard method with 
additional studies (measurement of waist circumferen-
ce, detection of cutaneous markers of insulin resistance 
(acanthosis nigricans of large skin folds, recurrent cuta-
neous papillomatosis)) and testosterone deficiency (gyne-
comastia). A special urological examination was also per-
formed for all the men included in the study (assessment 
of pubic hair distribution, examination and palpation of 
the scrotum and penis, finger rectal examination (FRE) 
of the prostate gland, according to the generally accepted 
methodology in urology). Laboratory diagnostics of insu-
lin resistance was carried out on the basis of simultaneous 
determination of blood plasma levels of glucose (glucose 
oxidase method) and insulin (by radioimmune analysis, or 
RIA). Blood sampling for the study was carried out from 
the peripheral (cubital) vein in the morning on an empty 
stomach. Laboratory diagnostics of testosterone deficien-
cy was carried out on the basis of simultaneous determi-
nation of the total testosterone level in blood plasma (by 
enhanced chemiluminescence using an automatic ana-
lyzer Vitros ECi (Ortho-Clinical Diagnostics, J&J, UK) 
and the level of globulin binding sex steroids (GBSS) by 
enzyme immunoassay (EI), using an automatic analyzer 
Elecsys 2010 (Hoffmann-La Roche)), followed by the 
calculation of the level of free testosterone using a special 
calculation formula available through specialized Internet 
services. Laboratory diagnosis of vitamin D deficiency 
was carried out in accordance with the Russian clinical 
recommendations Vitamin D Deficiency in Adults: Diag-
nosis, Treatment and Prevention on the basis of determi-
nation of the concentration of inactive form 25(OH)-vita-
min D in serum by enhanced chemiluminescence, as an 
objective generally accepted indicator of the adequacy of 
the D-status of the human body. Determination of total 
PSA level in blood serum was carried out by immunoche-
mical analysis (ICA) through electrochemiluminescence 
detection (ECLD), using an analyzer and a test system 
Cobas 6000 (Roche Diagnostics, Switzerland). To test the 
Table 1. Age Distribution in the Study Groups (n = 190).
Age 
(years)
Control group (n = 30) Main group (n = 160)
Absolute 
number (people)
Percentage (%) Absolute 
number (people)
Percentage (%)
45–55 9 30.0 42 26.3
55–65 10 33.3 54 33.7
65–75 11 36.7 64 40.0
Total 30 100.0 160 100.0
Table 2. Distribution of Patients with PA of the main group by the degree of severity of LUTS/PA and the quality of life index (QL)
(М ± m; n = 160).
Severity of LUTS/PA according to 
IPSS scale LQ (points)
Life quality index (LQ) (average score 
and confidence interval 0,95)
Absolute number of patients Percentage of the total number of 
patients (%)
0–7 (slight LUTS) 1.2 ± 0.6 (1–2) 78 48.8
8–19 (mild LUTS) 3.3 ± 0.3 (1–4) 61 38.1
20–22 (severe LUTS) 5.1 ± 0.2 (2–6) 21 13.1
Total 2.9 ± 0.3 (0–5) 160 100.0
Note: LUTS – lower urinary tract symptoms; PA – prostate adenoma; IPSS – International Prostate Symptoms Score; LQ –Life Quality.
Table 3. Frequency of nocturia and severity of LUTS in patients with PA (n = 160).
Degree of LUTS/PA severity according 
to IPSS-LQ scale (points) (Absolute 
number of patients and percentage of 
total number of patients)
Average frequency of nocturia 
(Absolute number of patients and 
percentage of total number of the 
corresponding group of patients)
Frequency of single nycturia 
(Absolute number of patients and 
percentage of number of patients with 
nycturia in this group)
Frequency of repeated nocturia 
(Absolute number of patients and 
percentage of patients with nocturia in 
this group)
0–7 (slight LUTS) (n = 78, or 48.8%) 43 (55.1%) 43 (55.1%) –
8–19 (mild LUTS) (n = 61, or 38.1%) 35 (57.4%) 20 (57.2%) 15 (42.8%)
20–35 (severe LUTS СНМП) (n = 21, 
or 13.1%)
18 (85.7%) 10 (55.5%) 8 (44.5%)
Total: (n = 160, or 100.0%) 96/160 (60.0%) 73/160 (45.6%) 23/160 (14.4%)
Note: LUTS – lower urinary tract symptoms; PA – prostate adenoma; IPSS –International Prostate Symptoms Score; LQ – Life Quality.
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reference parameters of healthy men (prostate volume, its 
structure, the amount of residual urine), as well as to as-
sess the initial morphometric parameters of the prostate 
and bladder and their dynamics during observation and 
pharmacotherapy, TRU was performed to all the men in-
cluded in the study of the main and control groups, using 
a 5.5 to 7 MHz rectal biplane probe (ultrasonic device 
”Ultramark-9”) and an ultrasonic complex Logiq 500 
Proseries. As a drug for pharmacological correction of vi-
tamin D deficiency, a drug Aquadetrim, licensed in Rus-
sia for the main indications, had been chosen, which was 
prescribed at the stage of starting the therapy at a daily 
dose of 10,000 IU once, and after the elimination of labo-
ratory vitamin D deficiency (plasma level of 25(OH)-vi-
tamin D > 75 nmol/l) – at a preventive dose of 3000 IU/
day once, in accordance with the Russian clinical recom-
mendations. The total duration of administering vitamin 
D-containg Aquadetrim to the D-deficient patients with 
PA was 12 months, during which its efficacy and safety 
were evaluated on the basis of periodic clinical, laborato-
ry and instrumental monitoring. Statistical processing was 
performed using Microsoft Excel 2007 and Statistica 6.0. 
(StatSoft, USA). The data were processed using descrip-
tive and comparative statistics. The results of the study 
were entered into a personal computer running Microsoft 
Excel–2007 and Statistica 6.0. The Spearman correlation 
coefficient (r) was determined to study the relationship of 
quantitative features among themselves. The Student’s 
criterion was used to estimate the intergroup differences 
in the feature values with a continuous distribution. To 
solve the tasks of studying the influence of two or more 
conditions on a certain random variable, various statisti-
cal methods of multivariate analysis were used. The cri-
tical level of reliability of the null statistical hypothesis 
(the absence of significant intergroup differences or factor 
influences) was assumed to be 0.05. The value of p < 0.05 
was considered statistically significant for all indicators 
generally accepted in biomedical studies.
Results and discussion
The study revealed a statistically significant higher fre-
quency of systemic hormonal and metabolic disorders in 
patients with PA compared with healthy men without PA. 
Thus, the incidence of obesity in patients with PA was 
42.5% versus 23.3% in healthy men without PA, that is 
on average 1.8 times more often (p < 0.05) (Fig. 1). At 
the same time, the incidence of obesity and the rate of 
its progression in patients with PA at a younger age (45–
55 years) was 1.8 times (26.5% vs. 14.3%; p < 0.05) and 
2.7 times, respectively, significantly higher, compared 
with men of the same age of the control group without 
PA (p < 0.05). Despite the fact that in the main and con-
trol groups there were no significant differences between 
the absolute values of plasma glucose level (glycemia), 
30.0% of patients of the main group had a significantly 
higher average blood insulin level compared to that in the 
control group (p < 0.05), which allowed detecting the la-
boratory symptom of hyper-insulinemia (insulin resistan-
ce) in them, the most common in obesity (Fig. 1.) The 
frequency of clinical and laboratory signs of testosterone 
Figure 1. Distribution of detected systemic hormonal and metabolic disorders in the main and control groups (frequency %).
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deficiency in patients with PA was 2 times significantly 
higher than that of men in the control group without PA 
(26.2% vs. 13.3%; p < 0.05) (Fig. 1.). As a characteristic 
feature of testosterone deficiency in PA should be conside-
red its early chronological manifestation in 16.7% of mid-
dle-aged men (45–55 years), and the most severe forms of 
testosterone deficiency in patients with PA were encoun-
tered in obese patients. The study also demonstrated an 
extremely high incidence of vitamin D deficiency in both 
the control group of men without PA (80.0%) and in the 
main group of patients with PA (84.3%) (p<0.1), which 
with age in both groups had similar trends to increase in 
both groups; however, men of the control group without 
PA had a significantly more compensated D-status (higher 
(on average 2.2-time) plasma levels of 25(OH)-vitamin 
D) compared with patients with PA of the main group 
(p < 0.05) (Fig. 1).
In the patients with PA and systemic hormonal and 
metabolic disorders, a negative relationship between the 
waist circumference and the free calculated testosterone 
level was revealed (n = 68; r = -0,265; p < 0.05); a po-
sitive relationship between the waist circumference and 
the blood insulin level (n = 68; r = + 0,312; p < 0.05) and 
a positive relationship between the level of 25(OH)-vita-
min D and the level of total blood testosterone (n = 135; 
r = +0,356; p < 0.05).
In the patients with PA and systemic hormonal and 
metabolic disorders (the main group), unlike the patients 
who did not have them, and the men of the control group 
as a whole, significantly worse local parameters of PA 
were revealed (p < 0.05). Thus, the total score of clinical 
symptoms according to the IPSS scale and the frequen-
cy of nocturia in patients with PA and systemic hormonal 
and metabolic disorders were 80.0% and 2.7 times signi-
ficantly higher, respectively, than in the patients with PA 
who did not have them (p < 0.05), which was accompan-
ied by a lower quality of life. In addition, the established 
fact of a higher (1.8-time) level of total blood PSA in the 
patients with PA and hormonal and metabolic disorders 
compared with the men without PA of the control group 
and the patients with PA without hormonal and metabo-
lic disorders, which, however, did not exceed the upper 
value of the reference range of the norm (p < 0.05), drew 
attention to itself. In the patients with PA and systemic 
hormonal and metabolic disorders, the average volume 
of the prostate gland was by 38.8%, and the amount of 
residual urine – by 73%, respectively, significantly higher 
than in the patients with PA without them, and on average 
– 2.5 and 6 times more, respectively, than in the control 
group (p < 0.05). The correlation multifactorial analysis 
in the patients with PA and systemic hormonal and meta-
bolic disorders revealed: a positive relationship between 
the waist circumference and the prostate volume (n = 60; 
r = + 0.289; p < 0.05); a positive relationship between the 
plasma level of insulin and the prostate volume (n = 60; 
r = + 0.413; p < 0.05); a significant negative relationship 
between the plasma level of total testosterone and the 
amount of residual urine (n = 60; r = -0.256; p < 0.05); a 
significant negative relationship between the plasma level 
of 25(OH)-vitamin D and the prostate volume (n = 60; 
r = -0,212; p < 0.05).
A comparative analysis of the impact of drug compen-
sation of vitamin D deficiency on the indicators of hor-
monal and metabolic status of patients and local parame-
ters of PA was conducted in two groups of D-deficient 
patients with PA and systemic hormonal and metabolic 
disorders: Group 1 (n = 40) did not receive the vitamin D 
drug and Group 2 (n = 40) received the vitamin D drug 
in accordance with the previously described design of the 
pharmacological part of the study. In the Group 1 patients, 
who were not treated with vitamin D, further progression 
of vitamin D deficiency was revealed (with a significant 
decrease in the average value of plasma 25(OH)-vitamin 
D from 16.3 ± 0.2 to 15.6 ± 0.3 nmol/L, respectively, or 
an average of 3.0%; p < 0.05) by the 12th month of the 
monitoring, which was accompanied by a progressive, 
although statistically insignificant, decrease in the level 
of total blood testosterone compared to its baseline le-
vel (from 13.4 ± 0.4 to 13.1 ± 0.5 nmol/L, respectively, 
or an average of 2.2%; p < 0.1) and a significant incre-
ase in the average level of plasma insulin compared to 
its baseline level (from 17.4 ± 0.8 to 19.6 ± 0.9 µed/ml, 
respectively, or an average of 12.6%; p < 0.05), indica-
ting progression of insulin resistance in the D-deficient 
patients with PA. On the contrary, along with the gradual 
elimination of vitamin D deficiency (normalization of the 
plasma level of 25(OH)-vitamin D) in the patients with 
PA of Group 2, starting with the 6th month of the vitamin 
D therapy (since the total elimination of laboratory vita-
min D deficiency in all the patients), there were positive 
changes in their hormonal and metabolic status, which by 
the 12th month of the therapy were in a significant incre-
ase in the total blood testosterone level by 15.6% from its 
initial level before the treatment (16,0 ± 0,3 nmol/L vs. 
14.1 ± 0.6 nmol/L, respectively) (p < 0.05) and in stabili-
zation of the plasma insulin level (stabilization of insulin 
resistance) (p < 0.1). The effect of the vitamin D therapy 
on the waist circumference in both groups was not statis-
tically significant (p > 0.1).
In Group 1, within 12 months, against the background 
of progression of systemic hormonal and metabolic di-
sorders, PA itself progressed as well (the average annual 
increase in its volume by transrectal ultrasound was an 
average of 1.9% (from 40.2 ± 1.5 cm3 to 44.9 ± 1.7 cm3, 
respectively) (p < 0.05). On the contrary, in Group 2, by 
the 12th month of the therapy with vitamin D, there was 
a significant 22.9% decrease in the volume of the prosta-
te gland compared to its initial volume before the treat-
ment (35.2 ± 0.9 cm3 versus 45.7 ± 1.3 cm3, respectively) 
(p < 0.05). At the same time, the amount of residual urine 
in the Group 2 patients by the 12th month of the therapy 
was on average by 23.3% significantly less than the same 
indicator of Group 1 without treatment (29.6 ± 2.6 ml vs. 
38.6 ± 2.4 ml; p < 0.05) (Fig. 2).
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For 12 months of the therapy, no fluctuations in the level 
of the total blood PSA suspicious for prostate cancer were 
observed, while the level of this marker in the patients 
of Group 2 was on average by 36.0% less than the same 
indicator in Group 1 (2.0 ± 0.3 ng/ml vs. 2.9 ± 0.4 ng/
ml, respectively; p<0.05), which indicated a high level of 
prostatic safety of the treatment with vitamin D.
Improvement of the hormonal and metabolic status 
and local parameters of PA in the Group 2 patients, when 
compensating for vitamin D deficiency, 12 months later 
resulted in the clinically significantly better indicators of 
the severity of LUTS/PA and the life quality index (LQI) 
compared with the patients of Subgroup 1, while the fre-
quency of nocturia in Group 2 significantly decreased 
from 30/40 (75.0%) to 19/40 (47.5%), i.e., on average, by 
27.5% from the initial (p < 0.05), in contrast to Group 1, 
where these indicators even further deteriorated (p < 0.1) 
by the 12th month of the dynamic observation (Fig. 3).
Thus, in patients with PA, a significantly higher 
frequency of concomitant systemic hormonal and me-
tabolic disorders (obesity – 42.5%, insulin resistance 
– 30.0%, testosterone deficiency – 26.2%, vitamin D 
deficiency – 84.3%) was established, which are usually 
formed at a younger age (45–55 years) compared with 
the men without PA (p < 0.05). Significant connections 
were established between them, which makes it possible 
to conclude about their close interaction and the ability 
to influence and aggravate each other. At the same time, 
in the patients with PA and systemic hormonal and meta-
bolic disorders, significantly worse local PA characteris-
tics (more pronounced LUTS/nocturia, lower quality of 
life, relatively higher level of total blood PSA, prostate 
volume and residual urine) were detected, unlike in the 
patients with PA without hormonal and metabolic discre-
dit and in the healthy men. The presence of significant 
links between the severity of obesity, insulin resistance, 
testosterone deficiency and vitamin D deficiency with 
local parameters of PA (prostate volume and amount of 
residual urine) allows considering them as the most im-
portant modern systemic hormonal and metabolic fac-
tors of PA pathogenesis.
A high frequency of vitamin D deficiency, both in the 
population of men without PA (80.0%) and in the patients 
with PA (84.3%), as well as the presence of more severe 
laboratory vitamin D deficiency in the patients with PA 
justify the pathogenetic feasibility of early detection and 
drug correction of vitamin D deficiency. According to the 
results of the present study, pharmacological compensati-
on of vitamin D deficiency in the patients with PA for 12 
months allows achieving a significant improvement of the 
Figure 2. Comparative characteristics of the dynamics of hormonal and metabolic status and local parameters of the prostate gland 
in patients with PA depending on the presence/absence of treatment with vitamin D (n = 80). Note: PG – prostate gland; PSA – 
prostate-specific antigen.
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Figure 3. Comparative dynamics of LUTS/PA severity (IPSS) and Life Quality Index (LQI) in patients of Groups 1 and 2 for 12 
months (n = 80). Note: LUTS – lower urinary tract symptoms; PA – prostate adenoma; IPSS – International Prostate Score Symp-
tom’s (international scale assessment of prostatic symptoms); LQ –Life Quality (life quality).
key local parameters of PA (reduce the severity of LUTS/
PA, reduce the frequency of nocturia by 27.5%, decrease 
the prostate volume by 22.9% and the amount of residual 
urine by 23.3% from the baseline). At the same time, it 
has a simultaneous positive effect on a systemic hormonal 
and metabolic status (in particular, on the androgen status 
(a significant increase in the level of total blood testos-
terone on average by 15.6% from baseline to the end of 
the therapy) and carbohydrate metabolism (stabilization 
of existing insulin resistance) without any side effects, 
with a high level of compliance and prostatic safety (sig-
nificant reduction in the total blood PSA level – by 36% 
from the baseline). All of that results in a significant im-
provement of life quality for the D-deficient patients with 
PA on the background of systemic hormonal and metabo-
lic disorders.
Therefore, drug compensation of vitamin D deficiency 
should be considered as the most important, effective and 
safe pharmacotherapeutic “first line” option in the treat-
ment of PA, since it predetermines both its independent 
positive prostatic antiproliferative effects and the effects 
associated with the improvement of the clinical course of 
testosterone deficiency and insulin resistance associated 
with vitamin D deficiency.
Based on the results of the study, an original integra-
tive model of hormonal and metabolic pathogenesis of PA 
was proposed (Fig. 4).
In this model, black solid arrows of various directions 
indicate the relationship between obesity, insulin resistan-
ce, testosterone deficiency and vitamin D deficiency, 
which has already been studied in numerous studies. The-
se arrows also show the potential mechanisms of influen-
ce that these systemic factors have on the local parameters 
of the prostate gland in PA, which have also been properly 
studied in a number of studies. Red dotted lines depict 
the relationship of systemic and local mechanisms in PA 
pathogenesis, established in the course of this study. The 
question marks in some of the mechanisms under conside-
ration refer to the presumptions (since no unambiguously 
objective and reliable confirmation of them was obtained 
in the course of this study), or they appeared in the course 
of this study, but they were not included in either its aims 
and objectives. It is clear that further evidence-based rese-
arch is needed to answer these questions. In order to opti-
mize the treatment and diagnostic search in case of PA to 
the fullest, against the background of systemic hormonal 
and metabolic disorders and on the basis of the results of 
the study, a optimized algorithms of the routine clinical 
practice to diagnose and manage patients with PA with 
hormonal and metabolic disorders were developed, based 
on interdisciplinary and integrative principles (Figs 5, 6.).
Thus, the proposed practical algorithms are designed 
to improve a traditional PA diagnostics carried out in a 
routine urological practice and to change the approaches 
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to the management of patients with the disease in order to 
improve its pathogenetic diagnostics and treatment and, 
perhaps, to outline some concrete ways of its prevention 
through early detection and effective therapy of all sys-
temic hormonal and metabolic factors identified during 
the examination of the patient with PA, in combination 
with the standard PA therapy by means of the medicines 
recommended in urology, mostly having only local effects 
on the vesico-urethro-prostatic segment of the male uro-
genital tract.
Conclusion
The results strongly suggest a significant role of systemic 
hormonal and metabolic disorders in men (obesity, insulin 
resistance, testosterone deficiency, vitamin D deficiency) 
in the multifactorial pathogenesis of PA in them. These 
findings can be considered as a clinical justification of a 
new direction in the PA pharmacotherapy, based on an 
integrative and interdisciplinary approach, namely – on 
mandatory diagnosis and subsequent correction of syste-
mic hormonal and metabolic disorders in all men with PA, 
against the background of taking specialized diagnostic 
and therapeutic measures within the existing standards of 
providing specialized medical care and clinical recom-
mendations of various levels.
The obvious prospects for subsequent development 
of an integrative approach to the diagnosis and treat-
ment of PA are believed to be further studies of these 
and other systemic hormonal and metabolic disorders 
potentially involved in the complex pathogenesis of PA, 
as well as a search for new drugs among pharmacologi-
cal agents with systemic and local effects in this disease 
in order to further optimize and improve the efficacy of 
the PA pharmacotherapy.
The promising area is definitely carrying out major 
evidence-based studies aimed at investigating the prop-
hylactic efficacy of the pharmacological correction of sys-
temic hormonal and metabolic disorders in PA, because 
an effective pathogenetic pharmacological prevention of 
the disease at the evidence-based methodological level 
has not been well developed yet.
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Figure 4. Integrative original model of hormonal and metabolic pathogenesis of PA, according to the results of the study.
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Figure 5. Practical algorithm of optimized diagnostics of hormonal and metabolic disorders and screening in patients with PA. Note: 
PA – prostate adenoma; LUTS – lower urinary tract symptoms; IPSS – International Prostate Score Symptom’s (international scale 
assessment of prostatic symptoms); LQ – Life Quality (quality of life); AMS – Aging Men Score (scale of evaluation of symptoms 
of aging men); GSPS – globulin binding sex steroids; PSA – prostate-specific antigen; Ultrasound-ultrasound examination; TRU – 
transrectal ultrasound examination.
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Figure 6. Practical algorithm of optimized diagnostics of hormonal and metabolic disorders and screening in patients with PA. Note: 
PA – prostate adenoma; PDE – 5-phosphodiesterase type 5.
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